Message-ID: <20667137.1075845192183.JavaMail.evans@thyme>
Date: Fri, 1 Jun 2001 13:31:49 -0700 (PDT)
From: brown_mary_jo@lilly.com
Subject: ***PRESS RELEASE*** In a New Phase III Study, CialisTM (IC351) 20
 mg Improved Erections in 85 Percent of Men With Erectile Dysfunction,
 Regardless of Severity
Cc: brown_mary_jo@lilly.com
Mime-Version: 1.0
Content-Type: text/plain; charset=us-ascii
Content-Transfer-Encoding: 7bit
Bcc: brown_mary_jo@lilly.com
X-From: BROWN_MARY_JO@LILLY.COM@ENRON <IMCEANOTES-BROWN+5FMARY+5FJO+40LILLY+2ECOM+40ENRON@ENRON.com>
X-To: alfred.gilman@email.swmed.edu, george.fisher@kodak.com, jterzuoli@ibjwhitehall.com, karen.n.horn@marsh.com, Lay, Kenneth </O=ENRON/OU=NA/CN=RECIPIENTS/CN=KLAY>, kseifert@kcc.com, prendergast@mayo.edu, scb@purdue.edu, win.bischoff@ssmb.com
X-cc: BROWN_MARY_JO@LILLY.COM
X-bcc: 
X-Folder: \Lay, Kenneth\Lay, Kenneth\Inbox
X-Origin: LAY-K
X-FileName: Lay, Kenneth.pst


The attached press release was issued over Business Wire this morning at 7:55 AM ET. 

 - Cialis Phase III Duration FINAL 060101.doc